F-fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with CT has revolutionized the staging of patients with head-and-neck cancer. FDG-PET/CT allows both anatomic and functional characterization of disease at the same time. Limited availability, costs, and falsepositive and -negative cases are disadvantages of the method (1).
Combinations of surgery, radiation, and chemotherapy are options for treatment in head-andneck cancer. Although the high doses of radiation used for treatment are effective, there is potential for significant toxicity, which leads to decreased quality of life and diminished patient compliance. Newer treatment modalities such as intensity-modulated radiation therapy and image-guided stereotactic radiosurgery aim to deliver radiation more efficiently and effectively. Essential to this is the accurate delineation of targets. During recent years, there has been interest in the use of integrated PET/ CT for radiotherapy planning. Gross tumor volume (GTV) at the primary site can predict local control of head-and-neck squamous cell carcinoma in patients who are treated with organ-preservation therapy. Previous studies comparing the GTVs of head-and-neck tumors based on CT and FDG-PET/CT have shown controversial results, i.e., an increase, decrease, or no change in GTV upon the addition of FDG-PET (1, 2).
In this issue of Acta Radiologica, MURAKAMI et al.
(3) report their experience of GTV assessment using FDG-PET/CT. They obtained FDG-PET/CT fused images for 20 patients with head-and-neck squamous cell carcinoma. All had undergone contrast-enhanced CT and MRI. GTV 1 and GTV 2 were designed without and with FDG-PET/CT, respectively. Observer A was a radiologist, and observer B a radiation oncologist. The authors found no systematic trend for volume difference between GTV 1 and GTV 2, and all tumors were visualized on FDG-PET/CT. Although the 95% limits of agreement were wider for interobserver than intermethod differences, the 95% limits of the interobserver agreement were narrower for GTV 2 than GTV 1. According to the authors, FDG-PET/ CT should not be used as a single modality but rather to obtain supplemental information for GTV assessment in this patient group (3). In a recent study, a high level of disease control combined with favorable toxicity profiles was achieved in a cohort of 42 head-and-neck carcinoma patients receiving PET/CT fusion-guided radiotherapy plus chemotherapy (4) (1). The pathogenesis of GBCA-induced NSF has focused mainly on one theory: instability in the gadolinium-containing chelates could cause release of free Gd 3' (2). Since free gadolinium is toxic, this could in turn cause fibrosis in the skin and other organs, perhaps through increasing activity of the so-called ''circulating fibrocytes.'' Several co-existent factors related to renal failure as such, or to the treatment thereof, have also been considered important for the development of GBCA-related NSF. One reason for the popularity of this ''instability hypothesis'' is the fact that the stability constants of the two GBCAs most strongly correlated to NSF (Omniscan, GE Healthcare, and Magnevist, Bayer Schering) are much lower than for most of the other GBCAs on the market. These two products could theoretically release more free gadolinium than the others.
Only a few biological experimental models have tested this prevailing hypothesis so far. Two of the most recent papers doing so will briefly be commented upon here.
The papers present very impressive models, and the authors should be honoured for pioneering these in order to improve the understanding of the pathogenesis of NSF.
SIEBER and co-workers developed a rat model simulating renal failure to investigate the role of NSF and the role of Gd and/or depletion of endogenous metal as possible triggers for NSF (3).
They gave high, repetitive doses of gadolinium ethylenediamine tetraacetic acid (Gd-EDTA), gadodiamide without excessive chelate (caldiamide) (Gd-DTPA-BMA), Omniscan, Magnevist, caldiamide, and normal saline to rats, six in each group. Doses of 2.5 mmol Gd/kg body weight were given 5 times per week over a period of 4 weeks. However, caldiamide and Gd-EDTA were given at lower doses, 0.5 mmol/kg and 0.1 mmol/kg, respectively, owing to the lower LD 50 of the substances.
Expected release of gadolinium, estimated from the stability constants, would be highest after Gd-EDTA and Gd-DTPA-BMA. Some of the main response parameters were macroscopic and microscopic skin changes. Macroscopic changes were seen after Gd-EDTA (6 of 6 rats), gadodiamide (6 of 6), and Omniscan (4 of 6). The mean severity scores were 1, 3.2, and 2.3, respectively. No visible skin changes were seen after Magnevist, caldiamide alone, or saline. Increased skin cellularity was seen after Gd-DTPA (6 of 6 rats), gadodiamide (6 of 6), and Omniscan (5 of 6). The severity scores were 1.5, 2.2, and 1, respectively. No increased cellularity was seen after Magnevist, caldiamide, or saline.
There are few critical comments that could be given to this otherwise elaborate study. However, the relevance of the dosing scheme to simulate the pharmacokinetics of renal failure is dubious. In a clinical situation of renal failure, only one dose will be given. Then, the concentration of the drug will gradually decline, dependent on the residual renal function. The applied dose regimen in this study will bring about a completely different pharmacokinetic of the drug. Further, the gadodiamide group had to be sacrificed after half the intended injections. The reason given was the severity of the skin lesions. Hence, the following concern must be
